Biogen Loses Multiple Sclerosis Treatment Patent On Appeal
European appellate officials have revoked a Biogen patent for a multiple sclerosis treatment, ruling that the pharmaceutical giant had wrongly narrowed its patented claims compared with the more general statements of...To view the full article, register now.
Already a subscriber? Click here to view full article